Results 151 to 160 of about 443,339 (310)

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

The intestine and human immunodeficiency virus [PDF]

Journal of Medical Microbiology, 1993
openaire   +2 more sources

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria

, 2010
O Erhabor1, Z A Jeremiah2, T C Adias1, Okere CE21Department of Medical Laboratory Sciences, College of Health Sciences, Niger Delta University, Wilbeforce Island, Bayelsa State, Nigeria; 2Department of Medical Laboratory Sciences, Rivers State University
Z A Jeremiah, T C Adias, et al, O Erhabor   +3 more
core  

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

Biopharmaceutics &Drug Disposition, EarlyView.
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula, Jeevan Sai Kallam, Aarika Kanukolanu, Ganesh Korada, Lakshmi Vineela Nalla   +4 more
wiley   +1 more source

Peripheral Arterial Disease in Human Immunodeficiency Virus Infection. [PDF]

Curr Atheroscler Rep
Mayne ES, Louw S, Freeman M, Funderburg N, Cassimjee I, Mayne ALH.   +5 more
europepmc   +1 more source

Design Space Assessment of Virus Inactivation in Plasma‐Derived Matrices Establishes a Single Detergent Alternative to TX‐100‐Containing Mixes

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The detergent Triton X‐100 (TX‐100) is a typical component of solvent/detergent (S/D) mixes applied for virus inactivation steps of biomanufacturing processes, yet environmentally unfavorable properties have led to restrictions on its use. Deviron 13‐S9 has recently been described as an eco‐friendly TX‐100 alternative, with powerful virus ...
Johanna Kindermann, Cecilie Klausen, Michael Karbiener, Thomas R. Kreil   +3 more
wiley   +1 more source

Longitudinal Changes in Cognition and Brain Imaging in Persons With Human Immunodeficiency Virus. [PDF]

J Infect Dis
Kennedy J, Cooley SA, Roman Fox J, Petersen KJ, Westerhaus E, Reid P, Lopez L, Ances BM.   +7 more
europepmc   +1 more source